Showing 1 - 20 results of 76,750 for search '(( significant decrease based ) OR ( significant ((a decrease) OR (sizes decrease)) ))', query time: 1.89s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. by Francesca Catto (21253435)

    Published 2025
    “…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”
  5. 5
  6. 6
  7. 7
  8. 8

    Image_1_The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy.TIF by Britta Hanssen (4898155)

    Published 2021
    “…To define the contribution of decreased muscle size to muscle weakness, two cohorts were recruited in this cross-sectional investigation: 53 children with SCP [median age, 8.2 (IQR, 4.1) years, 19/34 uni/bilateral] and 31 children with a typical development (TD) [median age, 9.7 (IQR, 2.9) years]. …”
  9. 9

    Table_2_The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy.docx by Britta Hanssen (4898155)

    Published 2021
    “…To define the contribution of decreased muscle size to muscle weakness, two cohorts were recruited in this cross-sectional investigation: 53 children with SCP [median age, 8.2 (IQR, 4.1) years, 19/34 uni/bilateral] and 31 children with a typical development (TD) [median age, 9.7 (IQR, 2.9) years]. …”
  10. 10

    Table_3_The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy.docx by Britta Hanssen (4898155)

    Published 2021
    “…To define the contribution of decreased muscle size to muscle weakness, two cohorts were recruited in this cross-sectional investigation: 53 children with SCP [median age, 8.2 (IQR, 4.1) years, 19/34 uni/bilateral] and 31 children with a typical development (TD) [median age, 9.7 (IQR, 2.9) years]. …”
  11. 11

    Table_1_The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy.docx by Britta Hanssen (4898155)

    Published 2021
    “…To define the contribution of decreased muscle size to muscle weakness, two cohorts were recruited in this cross-sectional investigation: 53 children with SCP [median age, 8.2 (IQR, 4.1) years, 19/34 uni/bilateral] and 31 children with a typical development (TD) [median age, 9.7 (IQR, 2.9) years]. …”
  12. 12
  13. 13

    Data_Sheet_2_The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy.docx by Britta Hanssen (4898155)

    Published 2021
    “…To define the contribution of decreased muscle size to muscle weakness, two cohorts were recruited in this cross-sectional investigation: 53 children with SCP [median age, 8.2 (IQR, 4.1) years, 19/34 uni/bilateral] and 31 children with a typical development (TD) [median age, 9.7 (IQR, 2.9) years]. …”
  14. 14

    Data_Sheet_1_The Contribution of Decreased Muscle Size to Muscle Weakness in Children With Spastic Cerebral Palsy.docx by Britta Hanssen (4898155)

    Published 2021
    “…To define the contribution of decreased muscle size to muscle weakness, two cohorts were recruited in this cross-sectional investigation: 53 children with SCP [median age, 8.2 (IQR, 4.1) years, 19/34 uni/bilateral] and 31 children with a typical development (TD) [median age, 9.7 (IQR, 2.9) years]. …”
  15. 15

    siRNA-based knockdown of <i>CLU</i> results in decreased VWF and CLU protein expression but no change in <i>VWF</i> mRNA content. by Allaura A. Cox (17980027)

    Published 2024
    “…<p>qPCR analysis of <i>CLU</i> expression demonstrates significant decrease in <i>CLU</i> expression after <i>CLU</i> siRNA knockdown (2A). …”
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20